About this Dosing Guide

This guide provides supplementary clinical context for the Atopic Dermatitis Biologic Dosing Calculator. It is intended for licensed healthcare professionals as a reference for understanding the calculator's outputs, dosing principles, and related clinical considerations for approved biologics in moderate-to-severe atopic dermatitis.

Outputs Explained

The calculator provides specific, guideline-based dosing recommendations based on the patient's age, weight, selected medication, and regulatory authority (FDA or EMA). The output typically includes:

• Loading Dose: The initial higher dose required to rapidly achieve therapeutic drug levels. This may consist of one or more administrations.
• Maintenance Dose: The regular, ongoing dose required to maintain therapeutic levels after the loading phase.
• Dosing Frequency: The interval for the maintenance dose, such as every 2 weeks or every 4 weeks.
• Patient Grouping: The specific age or weight cohort the patient falls into, which determines the dosing regimen.

How to Use the Calculator

To obtain a dosing recommendation, follow these steps:

1. Select Medication: Choose from Dupilumab, Tralokinumab, or Lebrikizumab.
2. Select Regulatory Authority: Choose between FDA (U.S.) and EMA (Europe) guidelines, as recommendations can differ.
3. Enter Patient Age: Provide the patient's age in years and months for accurate pediatric dosing.
4. Enter Patient Weight: Input the patient's weight and select the appropriate unit (kg or lbs).
5. Calculate: Click "Calculate Dose" to view the results. Always cross-reference the output with the official prescribing information.

Dosing Overview

Dosing strategies for biologics in atopic dermatitis are tailored to the specific drug's pharmacokinetics and the patient population. Dupilumab dosing is stratified by distinct age and weight bands, with different regimens for infants/young children (6 months - 5 years), older children (6 - 11 years), and adolescents/adults (≥12 years). Tralokinumab and Lebrikizumab are approved for adolescents and adults (≥12 years), with Tralokinumab having a different dose for adolescents versus adults, and Lebrikizumab requiring a minimum patient weight of 40 kg.

Switching Between Biologics

The decision to switch from one biologic to another is based on clinical judgment, considering factors like suboptimal response, adverse events, or patient preference. There are no standardized washout periods; a common approach is to administer the first dose of the new biologic at the time the next dose of the previous biologic would have been due. Consult specialist guidelines and prescribing information for specific recommendations.

Missed Dose Instructions

General guidance for a missed dose is to administer it as soon as possible. Afterwards, the regular dosing schedule should be resumed from the date of the most recent injection. For example, if a patient on an every-2-week schedule misses a dose and takes it 5 days late, their next dose should be 2 weeks after the late administration. Patients should be advised to consult their healthcare provider and the drug's specific patient information leaflet.

Safety Alerts

This calculator is a dosing aid and does not replace a full clinical assessment. Before prescribing, review the complete safety profile in the official Prescribing Information. Key safety considerations for this class of biologics may include injection site reactions, conjunctivitis, and hypersensitivity reactions. Ensure patients are properly trained on subcutaneous injection administration technique.

Frequently Asked Questions (FAQ)

Why does the calculator ask for regulatory authority (FDA vs. EMA)?

Prescribing guidelines can differ between regulatory bodies. For example, the FDA-approved label for Dupilumab in children aged 6-11 years (15 to <60 kg) specifies a loading dose, whereas the EMA label does not.

What should I do if a patient's weight changes significantly?

For medications with weight-based dosing, a significant change in weight may require a dose adjustment. Re-run the calculation and consult the prescribing information to see if the patient has crossed into a new dosing bracket.

Does the calculator account for comorbidities or concomitant medications?

No. The tool is strictly for calculating standard dosing based on approved labels for atopic dermatitis. It does not account for renal/hepatic impairment, drug interactions, or other clinical factors that might influence treatment decisions.

Is there a loading dose for all age groups for Dupilumab?

No. According to the product label, a loading dose is not recommended for the youngest age group (6 months to 5 years). The calculator's logic reflects this.

What is the minimum weight for Lebrikizumab according to the calculator?

The calculator enforces the label requirement that patients must be at least 40 kg to receive Lebrikizumab.

How is Tralokinumab dosing different for adolescents versus adults?

Adolescents (12-17 years) receive a lower loading dose (300 mg) and maintenance dose (150 mg Q2W) compared to adults (600 mg loading, 300 mg Q2W).

Can I use this calculator for off-label indications?

This tool is designed exclusively for the on-label dosing of the specified biologics in moderate-to-severe atopic dermatitis. It should not be used for other conditions or off-label dosing.

What should I do if the calculator's output seems incorrect?

Always consider the official, most current Prescribing Information or Summary of Product Characteristics as the single source of truth. If a discrepancy is found, follow the official documentation.

References

1. DUPIXENT® (dupilumab) Prescribing Information. Regeneron Pharmaceuticals, Inc. View FDA Label
2. ADBRY™ (tralokinumab-ldrm) Prescribing Information. LEO Pharma Inc. View FDA Label
3. Ebglyss (lebrikizumab) Summary of Product Characteristics. European Medicines Agency. View EMA Summary
4. U.S. Food and Drug Administration. Drugs@FDA Database. Access Database
5. European Medicines Agency. Medicines Database. Access Database